Yr Athro Emma Kidd
(Mae hi'n)

PhD FBPhS

Athro Ffarmacoleg, Cyfarwyddwr DTP MRC MRC GW4 BioMed2

Ysgol Fferylliaeth a Gwyddorau Fferyllol

: KiddEJ@caerdydd.ac.uk
: +44 29208 75803
: Adeilad Redwood , Ystafell 2.57B, Rhodfa'r Brenin Edward VII, Caerdydd, CF10 3NB

: Sylwebydd y cyfryngau
: Ar gael fel goruchwyliwr ôl-raddedig

Qualifications

BSc in Pharmacology, University of Bath, 1987
PhD in Neuropharmacology, University of Nottingham, 1990

Relevant websites

Alzheimer's Society
BRACE (Bristol Research into Alzheimer's and Care of the Elderly)
Alzheimers Research UK

Date
Type

2009

Broadley, K. J. et al. 2009. Effects of dietary amines on the gut and its vasculature. British Journal of Nutrition 101(11), pp. 1645-1652. (10.1017/s0007114508123431)
Alqallaf, S. M., Evans, B. A. J. and Kidd, E. J. 2009. Atypical P2X7 receptor pharmacology in two human osteoblast-like cell lines. British Journal of Pharmacology 156(7), pp. 1124-1135. (10.1111/j.1476-5381.2009.00119.x)

2008

Penson, P. E., Ford, W. R., Kidd, E. J. and Broadley, K. J. 2008. Activation of beta-adrenoceptors mimics preconditioning of rat-isolated atria and ventricles against ischaemic contractile dysfunction. Naunyn-Schmiedeberg's Archives of Pharmacology 378(6), pp. 589-597. (10.1007/s00210-008-0331-6)
Herbert, A. A., Kidd, E. J. and Broadley, K. J. 2008. Dietary trace amine-dependent vasoconstriction in porcine coronary artery. British Journal of Pharmacology 155(4), pp. 525-534. (10.1038/bjp.2008.286)
Fernandez-Rodriguez, S., Ford, W. R., Broadley, K. J. and Kidd, E. J. 2008. Establishing the phenotype in novel acute and chronic murine models of allergic asthma. International Immunopharmacology 8(5), pp. 756-763. (10.1016/j.intimp.2008.01.025)
Penson, P. E., Ford, W. R., Kidd, E. J. and Broadley, K. J. 2008. Protective role of beta 2- and beta 3-adrenoceptors at reperfusion in isolated rat heart. Journal of Molecular and Cellular Cardiology 44(4), pp. 719-719. (10.1016/j.yjmcc.2008.02.020)

2007

Alqallaf, S. M., Kidd, E. and Evans, B. A. J. 2007. Atypical pharmacology of P2X7 receptors in humanosteoblasts. Journal of Bone and Mineral Research (JBMR) 22(7), pp. 1135-1135.
Alqallaf, S., Kidd, E. and Evans, B. A. J. 2007. Modulation of P2X(7) receptors in human osteoblasts by oestrogen and corticosteroids. Presented at: 29th Annual Meeting of the American-Society-for-Bone-and-Mineral-Research, Honolulu, HI, 2007, Vol. 22. Amer Soc Bone & Mineral Res pp. S145-S145.

2006

Thomas, R. S., Liddell, J. E., Murphy, L. S., Pache, D. M. and Kidd, E. J. 2006. An antibody to the β-secretase cleavage site on amyloid-β-protein precursor inhibits amyloid-β production. Journal of Alzheimer's Disease 10(4), pp. 379-390.
Kidd, E. J., Clark, J., Martin, T. and Yates, L. 2006. Radioligand binding and functional response of ligands for human recombinant adenosine A3 receptors. Autonomic and Autacoid Pharmacology 26(2), pp. 191-200. (10.1111/j.1474-8673.2006.00372.x)

2003

Clark, J. H., Broadley, K. J., Hutcheson, I. R., Nicholson, R. I. and Kidd, E. J. 2003. Expression of adenosine receptors in MCF-7 human breast cancer cells [Abstract]. British Journal of Pharmacology 138, pp. U65.
Connon, C. J., Young, R. D. and Kidd, E. J. 2003. P2X7 receptors are redistributed on human monocytes after pore formation in response to prolonged agonist exposure. Pharmacology 67(3), pp. 163-168. (10.1159/000067795)

2002

Clark, J. H., Martin, T. J., Yates, L., Kidd, E. J., Nicholson, R. I. and Broadley, K. J. 2002. Characterisation of transfected human adenosine A3 receptors [Abstract]. British Journal of Pharmacology 136
Clark, J. H., Broadley, K. J., Hutcheson, I. R., Nicholson, R. I. and Kidd, E. J. 2002. Adenosine receptor agonists mediate the phosphorylation of mitogen activated protein kinase (MAPK) in MCF-7 human breast cancer cells [Abstract]. British Journal of Pharmacology 135

2001

Elneil, S., Skepper, J. N., Kidd, E. J., Williamson, J. G. and Ferguson, D. R. 2001. Distribution of P2X1 and P2X3 receptors in the rat and human urinary bladder. Pharmacology 63(2), pp. 120-128. (10.1159/000056122)
Elneil, S., Skepper, J. N., Kidd, E. J., Williamson, J. G., Sellers, L. A. and Ferguson, D. R. 2001. Evidence for differential expression of P2X(1) and P2X(3) purine receptors in the detrusor muscle and urothelium, respectively, in the rat and human urinary bladder [Abstract]. British Journal of Pharmacology 133, pp. U11.

2000

Souslova, V. et al. 2000. Warm-coding deficits and aberrant inflammatory pain in mice lacking P2X(3) receptors. Nature 407(6807), pp. 1015-1017. (10.1038/35039526)
Kidd, E. J., Michel, A. D., Grahames, C. M., Dawe, H. and Humphrey, P. P. A. 2000. P2X(7) receptor expression and function in human THP-1 cells [Abstract]. British Journal of Pharmacology 131
Hibell, A. D., Kidd, E. J., Chessell, I. P., Humphrey, P. P. A. and Michel, A. D. 2000. Apparent species differences in the kinetic properties of P2X(7) receptors. British Journal of Pharmacology 130(1), pp. 167-173. (10.1038/sj.bjp.0703302)

1998

Kidd, E. J., Miller, K. J., Sansum, A. J. and Humphrey, P. P. A. 1998. Evidence for P2X(3) receptors in the developing rat brain. Neuroscience 87(3), pp. 533-539. (10.1016/S0306-4522(98)00294-2)
Eriksson, J., Bongenhielm, U., Kidd, E. J., Matthews, T. and Fried, K. 1998. Distribution of P2X(3) receptors in the rat trigeminal ganglion after interior alveolar nerve injury. Neuroscience Letters 254(1), pp. 37-40. (10.1016/S0304-3940(98)00656-9)
Schindler, M. et al. 1998. Molecular cloning and functional characterization of a rat somatostatin sst(2(b)) receptor splice variant. British Journal of Pharmacology 125(1), pp. 209-217. (10.1038/sj.bjp.0702064)
Kidd, E. J., Schindler, M., Wyatt, M. A., Sellers, L. A. and Humphrey, P. P. A. 1998. Molecular cloning, expression and localisation of the rat somatostatin sst(2(b)) receptor splice variant in the rat gastric mucosa [Abstract]. British Journal of Pharmacology 123, pp. U82.

1997

Simon, J., Kidd, E. J., Smith, F. M., Chessell, I. P., Murrell-Lagnado, R., Humphrey, P. P. A. and Barnard, E. A. 1997. Localization and functional expression of splice variants of the P2X(2) receptor. Molecular Pharmacology 52(2), pp. 237-248.

1996

McKeen, E. S., Feniuk, W., Michel, A. D., Kidd, E. J. and Humphrey, P. P. A. 1996. Identification and characterisation of heterogeneous somatostatin binding sites in rat distal colonic mucosa. Naunyn Schmiedeburgs Archives of Pharmacology 354(5), pp. 543-549. (10.1007/BF00170826)
Holloway, S., Feniuk, W., Kidd, E. J. and Humphrey, P. P. A. 1996. Autoradiographical studies with the somatostatin sst(2)-receptor-selective novel radioligand [I-125]-BIM-23027 in rat brain [Abstract]. British Journal of Pharmacology 117(S1), pp. 320P. (10.1111/j.1476-5381.1996.tb17244.x)
Holloway, S., Feniuk, W., Kidd, E. J. and Humphrey, P. P. A. 1996. A quantitative autoradiographical study on the distribution of somatostatin sst(2) receptors in the rat central nervous system using [I-125]-BIM-23027. Neuropharmacology 35(8), pp. 1109-1120. (10.1016/S0028-3908(96)00082-2)

1995

Grahames, C. B. A., Kidd, E. J., Simon, J., Michel, A. D., Barnard, E. A. and Humphrey, P. P. A. 1995. Localization of P-2X-Purinoceptor Transcripts in the Rat Nervous-System [Abstract]. British Journal of Pharmacology 116(S1), pp. 138P. (10.1111/j.1476-5381.1995.tb16904.x)
Kidd, E. J., Grahames, C. B. A., Simon, J., Michel, A. D., Barnard, E. A. and Humphrey, P. P. A. 1995. Localization of P2X purinoceptor transcripts in the rat nervous system. Molecular Pharmacology 48(4), pp. 569-573.
Kidd, E. J., Michel, A. D. and Humphrey, P. P. A. 1995. Autoradiographic distribution of [3H]l-NG-Nitro-arginine binding in rat brain. Neuropharmacology 34(1), pp. 63-73. (10.1016/0028-3908(94)00132-C)

1994

Kidd, E., Michel, A. D. and Humphrey, P. P. A. 1994. Regional autoradiographic localization of high-affinity [H-3] alpha,beta-methylene ATP binding-sites in the rat-brain [Abstract]. British Journal of Pharmacology 112, pp. U165.
Jolas, T. et al. 1994. Central Pre- and Postsynaptic 5-HTIA Receptors in Rats Treated Chronically With a Novel Antidepressant, Cericlamine. Journal of Pharmacology and Experimental Therapeutics 268(3), pp. 1432-1443.

1993

Kidd, E. J., Michel, A. D. and Humphrey, P. P. A. 1993. Regional autoradiographic localization of nitric-oxide synthase in the rat-brain using [H-3] nitroarginine [Abstract]. British Journal of Pharmacology 110(S1), article number: P81. (10.1111/j.1476-5381.1993.tb16292.x)
Kidd, E. J., Levy, J. C., Nielsen, M., Hamon, M. and Gozlan, H. 1993. Characterisation of the non-5-HT3 high-affinity ‘R’ binding site for (R)-zacopride in brain and other tissues. European Journal of Pharmacology: Molecular Pharmacology 247(1), pp. 45-56. (10.1016/0922-4106(93)90136-W)
Jolas, T. et al. 1993. (−)Tertatolol is a potent antagonist at pre- and postsynaptic serotonin 5-HT1A receptors in the rat brain. Naunyn Schmiedeburgs Archives of Pharmacology 347(5), pp. 453-463. (10.1007/BF00166735)
Kidd, E. J. et al. 1993. 5-HT3 receptors in the rat central nervous system are mainly located on nerve fibres and terminals. Brain Research 612(1-2), pp. 289-298. (10.1016/0006-8993(93)91674-H)
Kidd, E. J. et al. 1993. New methoxy-chroman derivatives, 4[N-(5-methoxy-chroman-3-yl)N- propylamino]butyl-8-azaspiro-(4,5)-decane-7,9-dione [(+/-)-S 20244] and its enantiomers, (+)-S 20499 and (-)-S 20500, with potent agonist properties at central 5-hydroxytryptamine1A receptors. Journal of Pharmacology and Experimental Therapeutics 264(2), pp. 863-872.

1992

Kidd, E. J., Bouchelet de Vendegies, I., Levy, J. C., Hamon, M. and Gozlan, H. 1992. The potent 5-HT3 receptor antagonist (R)-zacopride labels an additional high affinity site in the central nervous system. European Journal of Pharmacology 211(1), pp. 133-136. (10.1016/0014-2999(92)90276-A)
Kidd, E. J., Laporte, A. M., Langlois, X., Lombard, M. C., Gozlan, H. and Hamon, M. 1992. Differential Localization and Regulation of Central 5-HT(1A) and 5-HT(3) Receptors. Presented at: Serotonin 9̀1 Conference, Birmingham, UK, 14-17 July 1991 Presented at Bradley, P. B. and Handley, S. L. eds.Serotonin, CNS Receptors and Brain Function: Proceedings of the Serotonin 9̀1 Conference held in Birmingham, UK, on 14-17 July 1991. Cospar Colloquia Series Vol. 85. Oxford: Pergamon Press pp. 13-27.

1991

Garratt, J. C., Kidd, E., Wright, I. K. and Marsden, C. A. 1991. Inhibition of 5-hydroxytryptamine neuronal activity by the 5-HT agonist, DOI. European Journal of Pharmacology 199(3), pp. 349-355. (10.1016/0014-2999(91)90499-G)
Kidd, E., Garratt, J. C. and Marsden, C. A. 1991. Effects of repeated treatment with 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) on the autoregulatory control of dorsal raphe 5-HT neuronal firing and cortical 5-HT release. European Journal of Pharmacology 200(1), pp. 131-139. (10.1016/0014-2999(91)90675-G)
Hamon, M., Lanfumey, L., Hajdahmane, S., Jolas, T., Kidd, E. J., Bolanos, F. and Gozlan, H. 1991. Adaptation of central 5-HT1A receptors after chronic antidepressant treatment in rats. Presented at: 5th World Congress of Biological Psychiatry, Florence, Italy, 9-14 June 1991 Presented at Racagni, G., Brunello, N. and Fukuda, T. eds.Biological Psychiatry: Proceedings of the 5th World Congress of Biological Psychiatry, Florence, 9-14 June 1991, Vol. 1. International congress series Vol. 968. Amsterdam: Excerpta Medica pp. 297-300.
Hamon, M., Kidd, E. J., Gozlan, H. and Martin, P. 1991. Is 5-HT3 receptor blockade able to prevent dopaminergic activation by stress. Presented at: 5th World Congress of Biological Psychiatry, Florence, Italy, 9-14 June 1991 Presented at Racagni, G., Brunello, N. and Fukuda, T. eds.Biological Psychiatry: Proceedings of the 5th World Congress of Biological Psychiatry, Florence, 9-14 June 1991, Vol. 2. International congress series Vol. 968. Amsterdam: Excerpta Medica pp. 706-709.

1990

Kidd, E. J., Leysen, J. E. and Marsden, C. A. 1990. Chronic 5-HT2 receptor antagonist treatment alters 5-HT1A autoregulatory control of 5-HT release in rat brain in vivo. Journal of Neuroscience Methods 34(1-3), pp. 91-98. (10.1016/0165-0270(90)90046-I)
Schotte, A. G., Kidd, E. J., Marsden, C. A. and Leysen, J. E. 1990. Autoradiographic measurement of 5-HT2 and 5-HT1C receptors in rat brain after chronic treatment with ritanserin and DOM [Poster]. European Journal of Pharmacology 183(5), pp. 1957-1958. (10.1016/0014-2999(90)92306-4)
Kidd, E. J., Leysen, J. E. and Marsden, C. A. 1990. Cortical 5-HT release in vivo after repeated treatment with a 5-HT2 agonist and a thyrotrophin releasing hormone analogue [Poster]. European Journal of Pharmacology 183(5), pp. 1948-1949. (10.1016/0014-2999(90)92296-U)

1988

Mir, A. K., Hibert, M., Tricklebank, M. D., Middlemiss, D. N., Kidd, E. J. and Fozard, J. R. 1988. MDL 72832: a potent and stereoselective ligand at central and peripheral 5-HT1A receptors. European Journal of Pharmacology 149(1-2), pp. 107-120. (10.1016/0014-2999(88)90048-9)

1987

Tricklebank, M. D., Neill, J., Kidd, E. J. and Fozard, J. R. 1987. Mediation of the discriminative stimulus properties of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) by the putative 5-HT1A receptor. European Journal of Pharmacology 133(1), pp. 47-56. (10.1016/0014-2999(87)90204-4)

Research interests

I am interested in understanding how alzheimer's disease develops and how it could be treated. Research in my laboratory is concentrated on cellular and molecular pharmacology to understand more about the mechanisms underlying several disease processes, with the ultimate aim of improving or developing new therapies for these conditions. We use a variety of human cell lines, animal models and human tissue and many biochemical and molecular biological techniques to investigate cell function.

Ageing in the brain
Alzheimer's disease
Development of models of respiratory disease

Director of Postgraduate Research Studies for the School of Pharmacy and Pharmaceutical Sciences

Novel therapeutic antibodies for Alzheimer's disease

Alzheimer's disease is a progressive neurodegenerative condition with very limited treatment and no cure. The incidence of this disease is rising worldwide as the population ages, as are the associated socioeconomic costs. There is therefore much interest in developing novel therapies. We proposed a 'blue skies' approach to devise an antibody-based therapy which would potentially halt the disease process and possibly also be used as a preventative treatment in high risk individuals. This approach differs to many others under investigation by other groups and companies worldwide and could be used in combination with other therapies to treat this debilitating and distressing disease.

Investigating how changes in endocytosis could give rise to Alzheimer's disease

It is highly likely that many factors contribute to the development of Alzheimer's disease. We are interested in changes in endocytosis, the process whereby cells take up material from the extracellular space. These changes have been identified in patients' brains and also as susceptibility genes which give a small, increased risk of developing Alzheimer's disease. We have manipulated a variety of proteins intimately involved in the two main types of endocytosis, clathrin-dependent and caveolin-dependent. Altering the levels of these proteins has contrasting effects on the levels of a number of proteins implicated in the pathogenesis of Alzheimer's disease.

Understanding the contribution of ageing to Alzheimer's disease

The main risk factor for Alzheimer's disease is increasing age but we still do not understand how ageing leads to the disease. Since endocytosis is known to be affected in Alzheimer's disease, we are examining how the expression of endocytic proteins is affected by ageing in mouse and human brains. We are investigating this using human brain samples from young, middle-aged and older people and comparing these results to those from people with Alzheimer's disease. We are also using a series of mouse brains from different ages and comparing normal mice and transgenic mice which are a model for Alzheimer's disease.

Development of asthma models

I am involved in the development of animal models of respiratory disease which more closely the mimic human disease. Such models will allow us to learn more about the pathophysiology of these conditions and may lead to novel or improved therapeutic drugs.

Collaborators

Postdoctoral research associates

Dr Mouhamed Alsaqati (funded by BRACE)

School of Pharmacy and Pharmaceutical Sciences

Prof Ken Broadley, Pharmacology & Physiology
Dr Will Ford, Pharmacology & Physiology
Dr Julia Gee, Pharmacology & Physiology
Prof Arwyn Jones, Pharmaceutical Biology
Dr Emma Lane, Pharmacology & Physiology
Dr Rhian Thomas, Pharmcology & Physiology

Cardiff University

Dr Dominic Dwyer, Psychology.
Prof Mark Good, Psychology
Prof Lesley Jones, Institute of Medical Genetics
Prof Paul Kemp, Biosciences
Dr Colin Powell, Child health
Prof Daniel Ricardi, Biosciences
Prof. Julie Williams, Psychological Medicine
Dr Nigel Willams, Psychological Medicine

Key expertise

Western blotting
Immunocytochemistry and immunohistochemistry with bright field and fluorescent microscopy including laser scanning confocal microscopy
ELISA
Cell culture techniques
RT-PCR
In situ hybridisation
In vivo measurements of lung function
sIRNA

Current research students

Charles Evans
Adam Brelsford

Previous research students

Dr Zakky Cholisoh
Dr Ceri Davies
Dr Alex Lowe
Dr Martha Hvoslef-Eide
Dr Gaudencio Natividad
Dr Jill Clark
Dr Sofia Fernandez-Rodriguez
Dr Martina Fehler
Dr Peter Penson
Dr Rhys Evans
Dr Dawn Turner
Dr Alex Henson
Dr Mohammed Al-Qallaf

Projects

Novel therapies and alzheimer's disease
Endocytosis and Alzheimer's disease
Ageing and alzheimer's disease
Development of models of respiratory disease.
Studies on the exacerbation of pulmonary inflammation by viral infection

PH1122 The role of the pharmacist in professional practice
PH1124 Human body systems
PH1125 Chemical and biological properties of drug molecules
PH2110 Clinical & professional pharmacy
PH2112 Principles of drug design
PH2113 Diseases and drugs I
PH3110 Optimisation of pharmaceutical care
PH3113 Diseases and drugs II
PH4116 Pharmacy research or scholarship project
PH4117 Pharmaceutical sciences, pharmacy practice and the population
PH4118 Pharmaceutical sciences, pharmacy practice and the patient

Career profile

I graduated with a degree in Pharmacology from the University of Bath in 1987 and then went to the Department of Physiology and Pharmacology at Nottingham University to do a Ph.D. on the "Functional Adaptation of 5-HT Receptors" under the supervision of Prof. Charles Marsden. Having graduated from Nottingham in 1990, I went to Paris to work for two years as a postdoctoral research associate in Dr Michel Hamon's INSERM-funded laboratory. In 1992 I returned to the U.K. to work as a Postdoctoral Research Associate and subsequently as a Senior Postdoctoral Research Associate for Prof. Pat Humphrey in the Glaxo Institute for Applied Pharmacology in the Department of Pharmacology at Cambridge University. In 1999, I joined the School of Pharmacy and Pharmaceutical Sciences at Cardiff University as a lecturer and was promoted to senior lecturer in 2009, and promoted again to Reader in 2013.

Scientific and professional service

External examiner in Pharmacology, University of East Anglia, MPharm degree.

Anrhydeddau a dyfarniadau

Awarded Fellowship of the British Pharmacological Society (2021)
Jointly awarded the Student Union’s Enriching Student Life Award for Personal Tutor of the Year (2020)
Jointly awarded the Student Union’s overall Enriching Student Life Award (2020)

Aelodaethau proffesiynol

Biochemical Society
Alzheimer's Society
British Neuroscience Association
British Pharmacological Society
Royal Pharmaceutical Society of Great Britain Academic Pharmacy Group
Alzheimers Association

Safleoedd academaidd blaenorol

Previous appointments

Reader in the School of Pharmacy and Pharmaceutical Sciences, 2013 – 2021
Senior Lecturer in the School of Pharmacy and Pharmaceutical Sciences, 2009-2013
Lecturer in the School of Pharmacy and Pharmaceutical Sciences, 1999 – 2009
Senior Postdoctoral Research Associate, University of Cambridge, 1997–1999
Postdoctoral Research Associate, University of Cambridge, 1992–1997
Postdoctoral Research Fellow, INSERM Unité 288, Paris, 1990–1992

Pwyllgorau ac adolygu

University Graduate College Board

I am interested in supervising students in the areas of:

The role of age and biological sex on the development of Alzheimer's disease
Management of depression and anti-psychotic use in patients with Alzheimer's disease
The influence of oestrogen exposure and the menopause on longevity

Prosiectau'r gorffennol

Graddiodd Dr Jill Clark, 'Effeithiau adenosine ar gelloedd canser y fron dynol', yn 2004.
Graddiodd Dr Sofia Fernandez-Rodriguez, 'Llwybrau signalau celloedd yn ymatebion llidiol y llwybrau anadlu mewn asthma', yn 2006.
Graddiodd Dr Mahmood Al-Qallaf, 'Nodweddu derbynyddion P2X₇ mewn osteoblasts dynol a modiwleiddio gan estrogen', yn 2008.
Graddiodd Dr Martina Fehler, 'Nodweddu derbynyddion olrhain amine yn y system gardiofasgwlaidd llygod mawr', yn 2008.
Graddiodd Dr Peter Penson, 'isdeipiau b-Adrenoceptor a llwybrau trawssefydlu sy'n ymwneud â chyflyru myocardaidd cyn ac ar ôl cyflyru', yn 2009.
Graddiodd Dr Rhys Evans, 'Modelau llid llwybrau anadlu cronig a ysgogwyd gan antigen dro ar ôl tro: swyddogaeth llwybrau anadlu a sensitifrwydd i asiantau gwrthlidiol', yn 2010.
Graddiodd Dr Dawn Turner, 'Mecanweithiau gweithredu cyfansoddion sy'n rhoi ocsid nitrig mewn modelau o asthma', yn 2010.
Graddiodd Dr Gaudencio Natividad, 'Unigedd a chymeriad cemegol a ffarmacolegol o antagonists derbynyddion aminau posibl o ffynonellau planhigion', yn 2011.
Graddiodd Dr Alex Henson, 'Ymchwilio i rôl adenosine yn nhwf celloedd canser y fron dynol', yn 2011.
Graddiodd Dr Martha Hvoslef-Eide, 'Nodweddu modelau llygoden mwtaniad APP trawsgenig o batholeg amyloid i'w defnyddio mewn imiwnotherapi cyn-glinigol', yn 2013.
Graddiodd Dr Alex Lowe, 'Rôl heintiau firaol a bacteriol mewn gwaethygu asthma a gwrthsefyll corticosteroid', yn 2013.
Graddiodd Dr Ceri Davies, 'In vivo examination of viral exacerbations of airways inflammation, function, mucus hypersecretion and mucociliary clearance', 2014.
Graddiodd Dr Zakky Cholisoh, 'Mecanweithiau ymwrthedd i weithredoedd steroid yn y llwybrau anadlu', 2014
Graddiodd Dr Charles Evans, 'Datblygu a nodweddu gwrthgorff protein rhagflaenydd gwrth-amyloid yn vivo fel therapi posibl ar gyfer clefyd Alzheimer', yn 2017.
Graddiodd Dr Shayda Maleki-Toyserkani, 'Ymateb Eicosanoid i haint mewn sepsis', 2019.
Graddiodd Dr Adam Brelsford, 'Iselder a dementia: Effaith patholeg ac ymyriadau therapiwtig Aβ ar brosesau affeithiol a gwybyddol mewn llygod', yn 2020.
Graddiodd Dr Thomas Freeman, 'Elucidating rôl protein rhagflaenydd amyloid yn y cof arferol', yn 2020.
Graddiodd Dr Jawza Almutairi, 'Deall sut mae oedran a rhywedd yn dylanwadu ar ddatblygiad clefyd Alzheimer', yn 2022.

Themâu ymchwil

Arbenigeddau

Clefyd niwroddirywiol
Niwrowyddoniaeth
Ffarmacoleg a gwyddorau fferyllol
Niwropharmacology
Menopos

Ysgol Fferylliaeth yn croesawu plant o ysgolion Cathays

Yr Athro Emma Kidd (Mae hi'n) PhD FBPhS

Trosolwyg

Qualifications

Relevant websites

Cyhoeddiad

2023

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010